NYSE:HTGC
Hercules Capital Inc Stock News
$19.07
+0.120 (+0.633%)
At Close: Apr 26, 2024
Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts
05:52pm, Friday, 14'th Oct 2022 Benzinga
BMO Capital Markets raised the price target on Replimune Group Inc (NASDAQ: REPL) to $40 from $30 on a bullish view into upcoming data readouts for lead asset RP1 in melanoma and cutaneous squam
Hercules Capital: I Am Happily Buying This Covered 12.41% Yield
10:24am, Saturday, 08'th Oct 2022
Hercules Capital offers investors a high yield plus growth. Portfolio is diversified and focuses on recession-proof business sectors.
Hercules Capital: Grab Its 13% Yield As Weak Holders Capitulate
12:56pm, Monday, 03'rd Oct 2022
Hercules Capital has been hammered as it remains nearly 40% below its April 2022 highs. We believe the de-rating is justified to de-risk the execution risks in its tech-focused portfolio companies. Ho
Hercules 11.5% Yield: 40 Big-Dividend BDCs Compared
05:45am, Wednesday, 28'th Sep 2022
Hercules Capital is an attractive, 11.5% yielding, internally-managed BDC with a differentiated strategy and a track record of success. However the shares have sold off hard, and there are significant
Implied Volatility Surging for Hercules (HTGC) Stock Options
11:59am, Friday, 09'th Sep 2022 Zacks Investment Research
Investors need to pay close attention to Hercules (HTGC) stock based on the movements in the options market lately.
Hercules Capital: 10% Yield, Wake Up And Smell The Cash Flow
08:05am, Wednesday, 31'st Aug 2022
Hercules Capital is a well-run lender to high-growth companies, with a focus on technology and life sciences companies. The company has been able to grow its originations and portfolio while maintaini
Akero Therapeutics (AKRO) Up on Positive NASH Study Data
03:53pm, Thursday, 25'th Aug 2022 Zacks Investment Research
Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.
Hercules Capital: 7% From An Investment Grade Bond With 4 Years To Maturity
11:49am, Tuesday, 23'rd Aug 2022
Hercules Capital has a rare mispriced issue with a YTM of 7%. Recently reviewed credit rating.
Zacks Industry Outlook Highlights Ares Capital, Golub Capital and Hercules Capital
09:00am, Friday, 19'th Aug 2022 Zacks Investment Research
Ares Capital, Golub Capital and Hercules Capital have been highlighted in this Industry Outlook article.
3 Stocks From the Thriving SBIC & Commercial Finance Industry
01:11pm, Thursday, 18'th Aug 2022 Zacks Investment Research
Higher rates, decent economic growth, robust asset quality and regulatory changes will keep aiding the Zacks SBIC & commercial finance industry players like Ares Capital (ARCC), Golub Capital (GBDC) a
Robust Loan Originations Aid Hercules Capital (HTGC) Top Line
02:30pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Driven by the growing demand for customized financing, Hercules Capital's (HTGC) top line is expected to keep improving.
Robust Loan Originations Aid Hercules Capital (HTGC) Top Line
12:02pm, Wednesday, 10'th Aug 2022
Driven by the growing demand for customized financing, Hercules Capital's (HTGC) top line is expected to keep improving.
FS KKR Capital (FSK) Q2 Earnings Beat Despite Higher Expenses
12:28pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Rise in total investment income and decent portfolio activity support FS KKR Capital's (FSK) Q2 earnings.
Hercules Capital: I Am Getting A 10.9% Yield On My Latest Buy
09:48am, Sunday, 31'st Jul 2022
Hercules Capital's portfolio kept performing extremely well in 2Q-22. Non-accruals remained at a very low level.
Hercules Capital: Good Q2 Earnings, 12% Yield, 6% Dividend Hike
09:15am, Sunday, 31'st Jul 2022
Hercules Capital just raised its upcoming dividend by 6%, to $.32. It'll also pay a $.15 supplemental dividend again in August.
